Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1945]

Outcome of ovarian cancer patients was significantly improved with niraparib

Dr Mansoor Raza Mirza - Copenhagen University Hospital, Copenhagen, Denmark

Outcome of ovarian cancer patients was significantly improved with niraparib ( Dr Mansoor Raza Mirza - Copenhagen University Hospital, Copenhagen, Denmark )

Ipilimumab as adjuvant therapy improves OS in high risk melanoma

Prof Alexander Eggermont - Institut Gustave Roussy, Villejuif, France

Ipilimumab as adjuvant therapy improves OS in high risk melanoma ( Prof Alexander Eggermont - Institut Gustave Roussy, Villejuif, France )

Ribociclib improves PFS for postmenopausal women with hormone receptor-positive...

Dr Gabriel Hortobagyi - MD Anderson, Houston, USA

Ribociclib improves PFS for postmenopausal women with hormone receptor-positive breast cancer ( Dr Gabriel Hortobagyi - MD Anderson, Houston, USA )

Immunotherapy and treatment advances in small cell lung cancer

Prof Dean Fennell - University of Leicester, Leicester, UK

Immunotherapy and treatment advances in small cell lung cancer ( Prof Dean Fennell - University of Leicester, Leicester, UK )

Combining drugs with radiotherapy

Prof John Staffurth - Cardiff University, Cardiff, UK

Combining drugs with radiotherapy ( Prof John Staffurth - Cardiff University, Cardiff, UK )

A novel biomarker for paediatic tumours

Dr Kathleen Birley - UCL Institute of Child Health, London, UK

A novel biomarker for paediatic tumours ( Dr Kathleen Birley - UCL Institute of Child Health, London, UK )

NSCLC biology and new therapies: Immunotherapies

Dr Rafael Rosell - Catalan Institute of Oncology, Barcelona, Spain

NSCLC biology and new therapies: Immunotherapies ( Dr Rafael Rosell - Catalan Institute of Oncology, Barcelona, Spain )

Immunotherapy in lung cancer: Q & A

Prof Giuseppe Giaccone and Dr Olivier Pardo

Immunotherapy in lung cancer: Q & A ( Prof Giuseppe Giaccone and Dr Olivier Pardo )

Immunotherapy in SCLC

Prof Dean Fennell - University of Leicester, Leicester, UK

Immunotherapy in SCLC ( Prof Dean Fennell - University of Leicester, Leicester, UK )

Immunotherapy in NSCLC

Prof Giuseppe Giaccone - Georgetown University, Washington DC, USA

Immunotherapy in NSCLC ( Prof Giuseppe Giaccone - Georgetown University, Washington DC, USA )

We should use PDL1 and other biomarkers for selecting patients for immune...

Dr Mary O’Brien - The Royal Marsden NHS Foundation Trust, London, UK

We should use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies ( Dr Mary O’Brien - The Royal Marsden NHS Foundation Trust, London, UK )

We should not use PDL1 and other biomarkers for selecting patients for immune...

Prof Gordon McVie - King's College London, London, UK

We should not use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies ( Prof Gordon McVie - King's College London, London, UK )

More from ecancer